Kraig Biocraft Laboratories, Inc.: Form 10-Q for the period ended Sep 30, 2015
Filed with the SEC on Nov 5, 2015 and accepted by EDGAR at Nov 5, 2015, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-07-01 to 2015-09-30 | $0 | us-gaap:SalesRevenueNet |
| Revenue | 9 months2015-01-01 to 2015-09-30 | $0 | us-gaap:SalesRevenueNet |
| Research and development | 3 months2015-07-01 to 2015-09-30 | $90.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2015-01-01 to 2015-09-30 | $313.7k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-07-01 to 2015-09-30 | −$322.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2015-01-01 to 2015-09-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-07-01 to 2015-09-30 | $25.7k | us-gaap:InterestExpense |
| Interest expense | 9 months2015-01-01 to 2015-09-30 | $71.4k | us-gaap:InterestExpense |
| Income tax | 3 months2015-07-01 to 2015-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2015-01-01 to 2015-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-07-01 to 2015-09-30 | −$348.5k | us-gaap:NetIncomeLoss |
| Net income | 9 months2015-01-01 to 2015-09-30 | −$1.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-07-01 to 2015-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2015-01-01 to 2015-09-30 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2015-01-01 to 2015-09-30 | −$685.1k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2015-01-01 to 2015-09-30 | $39.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-09-30 | $220.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-09-30 | $220.9k | us-gaap:AssetsCurrent |
| Total assets | At period end2015-09-30 | $291.3k | us-gaap:Assets |
| Current liabilities | At period end2015-09-30 | $2.1m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2015-09-30 | −$1.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001354488-15-004837. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.